CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...8081828384858687888990...39323933»
  • ||||||||||  Orencia (abatacept) / BMS
    Journal, IO biomarker:  CD4+CD8?low T cells in rheumatoid arthritis are clonally expanded and dependent on co-stimulation. (Pubmed Central) -  Jul 27, 2024   
    In addition, the combination of MTA and NCCN-IPI may be helpful in further improving risk stratification and guiding individualised treatment options. In RA, clonal expansion of CD4+ T cell clones culminates in the emergence of peripheral CD4+CD8?low T cells, which are associated with disease activity and diminished upon abatacept treatment, and which could contribute to disease pathogenesis.
  • ||||||||||  Journal, Adverse events, Checkpoint inhibition:  Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database. (Pubmed Central) -  Jul 26, 2024   
    The LAG-3 inhibitor relatlimab reported fewer AEs, including pyrexia and pneumonia...This study provides a detailed overview of the 25 most common AEs associated with ICIs, offering valuable insights for clinical decision-making and AE management. Further research is necessary to elucidate the mechanisms underlying these AEs and to develop targeted interventions to enhance the safety and efficacy of ICI therapy in patients with cancer.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Journal, Adverse events, Real-world evidence, Real-world:  Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data. (Pubmed Central) -  Jul 26, 2024   
    Despite the morbidity associated with these adverse events, emerging evidence suggests potential associations with improved survival outcomes. Overall, this report sheds light on the widespread immune-related adverse events that cause significant morbidity and mortality in patients with cancer being treated with atezolizumab and brings attention to them for the clinicians treating these patients.
  • ||||||||||  sunitinib / Generic mfg.
    Preclinical, Journal:  177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model. (Pubmed Central) -  Jul 26, 2024   
    Our study successfully developed 177Lu-DOTA-ATPS mAb, a radioimmunotherapy agent targeting tumor blood vessels. This approach demonstrates significant promise for inhibiting tumor growth, both as a single therapy and in combination with other anti-cancer drugs.
  • ||||||||||  Review, Journal, Checkpoint inhibition:  The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer. (Pubmed Central) -  Jul 26, 2024   
    In the first-line treatment setting, options include pembrolizumab alone or in combination with bevacizumab, as well as atezolizumab combined with a backbone platinum-based chemotherapy plus bevacizumab...For endometrial cancer, pembrolizumab monotherapy, pembrolizumab in combination with lenvatinib, and dostarlimab are currently approved as second-line treatment options...Although the inclusion of these agents in clinical practice has led to improved overall response rates and survival outcomes, many patients still lack benefits, possibly due to multiple intrinsic and adaptive resistance mechanisms to immunotherapy. This review aims to highlight the rationale for utilizing ICIs and their current role, while also delineating the proposed mechanisms of resistance to ICIs in cervical and endometrial cancer.
  • ||||||||||  Clinical, Retrospective data, Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores. (Pubmed Central) -  Jul 26, 2024   
    In advanced ESCC patients irrespective of PD-L1 expression, both sintilimab-chemotherapy and toripalimab-chemotherapy regimens demonstrated comparable OS benefits (HR=0.92, 95% CI: 0.64-1.33)...Notably, camrelizumab-chemotherapy (HR=0.83, 95% CI: 0.59-1.16) and nivolumab-ipilimumab (HR=0.84, 95% CI: 0.60-1.17) demonstrated significant safety profiles over chemotherapy alone...Among patients with PD-L1 expression ?10%, camrelizumab-chemotherapy (HR=0.52, 95% CI: 0.35-0.78) emerged as the most efficacious in improving OS, while serplulimab-chemotherapy (HR=0.48, 95% CI: 0.34-0.68) was associated with the longest PFS benefit...Since most of the patients in this study originated from Asia, the above findings are more applicable to the Asian population. https://www.crd.york.ac.uk/prospero/, identifier CRD42024504992.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Clinical, PK/PD data, Journal:  Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers. (Pubmed Central) -  Jul 26, 2024   
    P1
    It is recommended to avoid concomitant administration of moderate inducers of CYP3A4 during treatment with SHR6390. http://www.chinadrugtrials.org.cn/index.html, CTR20211571/ https://classic.clinicaltrials.gov, NCT04973020.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, FDG PET:  Pembrolizumab-induced vasculitis demonstrated by FDG-PET/CT. (Pubmed Central) -  Jul 26, 2024   
    Subsequent FDG-PET/CT performed 14 months after initiation of treatment for vasculitis demonstrated resolution of vasculitis. Immune checkpoint inhibitors can cause vasculitis, which can be recognized on FDG-PET/CT and lead to appropriate treatment.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  CaCO3-Encapsulated polydopamine with an adsorbed TLR7 agonist for improved tumor photothermal immunotherapy. (Pubmed Central) -  Jul 26, 2024   
    PICB had a strong inhibitory effect on tumor growth in 4T1 tumor-bearing mice, and has no toxicity to other organs. Therefore, the multifunctional drug delivery nanosystem constructed in this study could effectively exert the properties of various components in vivo, fully demonstrate the synergistic effect between immunotherapy and photothermal therapy, thus significantly improving the tumor therapeutic efficacy, and has a promising clinical application.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  An Unusual Case of Neurofascin 186 Neuropathy. (Pubmed Central) -  Jul 26, 2024   
    NF 186, also known as neurofascin 186, is a cell adhesion molecule crucial for the integrity and functioning of the peripheral nervous system. This case report highlights the clinical presentation specific to NF 186-positive autoimmune neuropathy and also the treatment modalities.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Unmasking Focal Segmental Glomerulosclerosis in a Patient With Lupus Nephritis. (Pubmed Central) -  Jul 26, 2024   
    This case underscores the importance of renal biopsies in SLE management to accurately diagnose and tailor treatment. It highlights the need to consider alternative renal complications, such as FSGS, which can coexist with lupus nephritis, necessitating a collaborative approach between rheumatologists and nephrologists to achieve optimal patient outcomes.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal, Minimal residual disease:  Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. (Pubmed Central) -  Jul 26, 2024   
    P3
    The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival. (Funded by the National Institutes of Health and others; E1910 ClinicalTrials.gov number, NCT02003222.).
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Journal, IO biomarker:  How I treat post-immunotherapy relapsed B-ALL. (Pubmed Central) -  Jul 26, 2024   
    We explore treatment modalities including CD19-CAR re-infusions, humanized CAR constructs, combinatorial strategies, and alternative antigen-targeted therapies, such as blinatumomab and inotuzumab. Challenges in diagnosis, particularly with antigen-escape, are addressed, highlighting the role of next-generation sequencing and multiparameter flow cytometry for myeloid marker monitoring.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca
    Journal, PD(L)-1 Biomarker, IO biomarker:  The PD-1 /PD-L1 signaling pathway regulates decidual macrophage polarization and may participate in preeclampsia. (Pubmed Central) -  Jul 26, 2024   
    Compared with that in the untreated group, the aggressiveness of HTR8/SVneo cells was decreased in both the pembrolizumab group (P < 0.01) and the durvalumab group (P < 0.001). These findings indicate that the PD-1/PD-L1 signaling pathway may play an important role in the pathogenesis of PE by influencing macrophage polarization and reducing the invasion ability of trophoblasts.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J, Carvykti (ciltacabtagene autoleucel) / J&J, Blenrep (belantamab mafodotin-blmf) / GSK
    Journal, IO biomarker:  Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. (Pubmed Central) -  Jul 26, 2024   
    Low-to-undetectable peripheral blood soluble BCMA levels correlated with the absence of BCMA expression by bone marrow plasma cells. Thus, although rare, loss of BCMA expression following TNFRSF17 gene deletions can occur following any BCMA-directed therapy and prevents response to subsequent anti-BCMA-directed treatments, underscoring the importance of verifying the presence of a target antigen.
  • ||||||||||  Rituxan (rituximab) / Roche
    Retrospective data, Journal:  Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study. (Pubmed Central) -  Jul 26, 2024   
    Thus, although rare, loss of BCMA expression following TNFRSF17 gene deletions can occur following any BCMA-directed therapy and prevents response to subsequent anti-BCMA-directed treatments, underscoring the importance of verifying the presence of a target antigen. Steroid dose was associated with lower height z-score, while rituximab use was associated with higher height z-score.
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    P2 data, Journal, Post-transplantation:  Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial. (Pubmed Central) -  Jul 26, 2024   
    Steroid dose was associated with lower height z-score, while rituximab use was associated with higher height z-score. Treatment response on interim scan and baseline International Prognostic Index were used to allocate patients to either a low-risk arm (who continued ibrutinib, alongside 4 further doses of 3-weekly rituximab) or high-risk (escalation to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone